Form 4 for MGX Metagenomi Therapeutics, Inc.
Accepted 2024-09-06 00:00:00 ET · period of report 2024-09-05 · accession 0000950170-24-104439 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-06 | 2024-09-05 | MGX | Wapnick Pamela | CFO | S - Sale | $2.88 | -6,265 | 63.1K | -9% | -$18.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-05 | S | D | 6,265 | $2.88 | 63,051 | D | — | — | (F2) The shares were sold in multiple transactions ranging from $2.80 to $2.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shars sold at each price. |